Kinases (Tyrosine Specific Protein)
Tyrosine specific kinases form a large family of enzymes that are responsible for catalyzing the transfer of ATP to specific tyrosine residues in target proteins. In turn, the phosphorylation of tyrosine residues causes a change in the function of the protein that they are contained in. They function in a variety of processes, signal transduction pathways, and actions, and may be responsible for key events in the body[1]. Axon Ligands™ that interact with tyrosine specific enzymes that are part of the JAK/STAT signaling pathway have been categorized independently. The remainder of Axon Ligands™ that lack interactions with tyrosine kinases of this particular signaling pathway are listed here, grouped on the basis of their selectivity.
[1] Receptor tyrosine kinase signaling: a view from quantitative proteomics. J. Dengjel,I. Kratchmarova, B. Blagoev. Mol. Biosyst. 2009, 5, 1112-1121.
| Axon ID | Name | Description | From price | |
|---|---|---|---|---|
| 3789 | YH-306 | FAK inhibitor | €90.00 | |
| 2762 | XMD 8-87 | Potent and selective inhibitor of Ack1 tyrosine kinase (also known as TNK2) | €95.00 | |
| 3973 | XL-228 | Multitargeted protein kinase inhibitor (IGF1R, Aurora,FGFR, ABL,ALK and SRC) | Inquire | |
| 2231 | XL 019 | JAK2 inhibitor | €100.00 | |
| 2316 | WP 1066 | Potent JAK2 and STAT3 inhibitor and downregulator of antiapoptotic proteins | €95.00 | |
| 2381 | WH-4-023 | Orally active src-family selective lck inhibitor | €90.00 | |
| 2072 | Tofacitinib citrate | Potent Janus Kinase 3 (JAK3) inhibitor | €115.00 | |
| 3099 | TL02-59 | Potent, selective and orally active Fgr and Lyn inhibitor | €120.00 | |
| 2560 | Tilfrinib | Brk inhibitor with antiproliferative activity in breast tumor cells | €95.00 | |
| 1588 | TG 101348 | JAK2 inhibitor | €80.00 | |
| 3866 | TAE226 | Potent and ATP-competitive dual FAK and IGF-1R inhibitor | €110.00 | |
| 1136 | SU 6656 | SRC kinase inhibitor | €120.00 | |
| 2130 | Stem Cell Alternative 2i inhibitor Set | Set of SRC inhibitor CGP77675 (Axon 2097) and GSK-3 inhibitor CHIR99021 (Axon 1386) | €110.00 | |
| 2778 | Squarunkin A | Selective UNC119–cargo interaction inhibitor | €125.00 | |
| 2539 | Solcitinib | Selective JAK1 inhibitor for treatment of degenerative and inflammatory diseases | €90.00 | |
| 1407 | SKI 606 | Bcr-Abl and Src tyrosine kinase inhibitor | €75.00 | |
| 3284 | Saracatinib | Inhibitor of SRC and ABL tyrosine kinases | €70.00 | |
| 1598 | Ruxolitinib | JAK1 and JAK2 inhibitor | €65.00 | |
| 3668 | RP-6306 | First-in-class, potent, selective, and orally bioavailable PKMYT1 inhibitor | €140.00 | |
| 3869 | RN486 | Selective and reversible inhibitor of Bruton's tyrosine kinase (BTK) | Inquire | |
| 1674 | R406 | Spleen tyrosine kinase Inhibitor | €80.00 | |
| 2459 | PND 1186 | Orally active dual FAK/PYK2 inhibitor triggering cell apoptosis in tumor cells | €90.00 | |
| 4215 | PF-562271 | Potent, selective, ATP-competitive and reversible dual FAK/PYK2 inhibitor | €110.00 | |
| 2217 | PF 956980 | JAK3 inhibitor; analogue of Axon 1338 and 2072 | €90.00 | |
| 1623 | PF 573228 | FAK inhibitor | €95.00 | |
| 2107 | PF 431396 | Dual FAK(PTK2) and PYK2 inhibitor | €80.00 | |
| 2110 | PF 06465469 | Inhibitor of interleukin-2 inducible T cell kinase (ITK) | €120.00 | |
| 2023 | PF 03814735 | ATP-competitive inhibitor of aurora kinase A and B | €120.00 | |
| 3950 | Peficitinib | Potent and orally bioavailable JAK inhibitor | €120.00 | |
| 1858 | PCI 32765 | Inhibitor of Bruton's tyrosine kinase (BTK) | €60.00 | |